Stock INTI INHIBITOR THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Inhibitor Therapeutics, Inc.

Equities

INTI

US45720M1053

Delayed OTC Markets
Other stock markets
 17:50:14 06/05/2024 BST 		5-day change 1st Jan Change
0.117 USD -0.85% Intraday chart for Inhibitor Therapeutics, Inc. +36.05% +27.17%
03-29 Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Introducing Inhibitor Therapeutics, Inc. Announces Scientific Advisory Board CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Introducing Inhibitor Therapeutics, Inc. New Scientific Advisory Board
AQ
Introducing Inhibitor Therapeutics, Inc. Announces Scientific Advisory Board
CI
Inhibitor Therapeutics, Inc. Announces the Use of Itraconazole to Treat Basal Cell Carcinoma Nevus Syndrome
CI
Inhibitor Therapeutics, Inc. Enters into an Exclusive, Worldwide Licensing Agreement with Johns Hopkins University
CI
Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University
PR
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Inhibitor Therapeutics, Inc. Appoints Michelle Yanez as an Independent Director and a Member of the Audit Committee
CI
Inhibitor Therapeutics, Inc. Appoints Ronald E. Osman as Non-Independent Director on the Board
CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
INHIBITOR THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
Inhibitor Therapeutics, Inc. Announces Board Changes
CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
INHIBITOR THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)
AQ
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
INHIBITOR THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Changes in Control or Registrant, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AQ
INHIBITOR THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Inhibitor Therapeutics : NOTICE OF PENDENCY OF DERIVATIVE AND CLASS ACTIONS, PROPOSED SETTLEMENT AND SETTLEMENT HEARING - Form 8-K
PU
INHIBITOR THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INTI Stock
  4. News Inhibitor Therapeutics, Inc.